Overview
- NewLimit announced the $435 million Series C financing on Tuesday and is now valued at about $3.1 billion after a round led by Founders Fund with participation from Thrive Capital, Lilly Ventures, Nat Friedman, and Daniel Gross.
- The company says it will use the money to move its lead liver program from preclinical work into regulatory filings and clinical setup aimed at first-in-human testing in 2027.
- NewLimit’s approach uses partial epigenetic reprogramming, meaning it delivers transcription factors to change gene-expression patterns associated with cellular aging without altering DNA sequences.
- Key risks remain because the work is untested in people and the evidence driving the valuation comes from cell and animal studies; safety concerns include the cancer risk tied to full reprogramming and challenges in reliably delivering factors with lipid nanoparticles.
- The raise highlights growing tech and venture interest in longevity drug development and will expand NewLimit’s clinical and regulatory teams while offering an early test of whether preclinical rejuvenation results translate into measurable benefit for patients.